Skip to main content
Top
Published in: Journal of Clinical Immunology 6/2016

01-08-2016 | Original Article

X-linked Hyper IgM Syndrome Presenting as Pulmonary Alveolar Proteinosis

Authors: Joel Gallagher, Juan Adams, Mary Hintermeyer, Troy R. Torgerson, Jesus Lopez-Guisa, Hans D. Ochs, Sara Szabo, Mina Salib, James Verbsky, John Routes

Published in: Journal of Clinical Immunology | Issue 6/2016

Login to get access

Abstract

Purpose

X-linked hyper IgM syndrome (XHIGM) is a combined immunodeficiency caused by mutations in the CD40 ligand (CD40L) gene that typically results in decreased or absent CD40L expression on activated T cells, leading to defective class switching and somatic hypermutation. We describe an infant who presented with respiratory failure due to pulmonary alveolar proteinosis (PAP) with a novel damaging missense mutation in the CD40L gene.

Methods

Whole exome sequencing (WES) was used to identify a mutation in the CD40L gene. CD40L expression and function were determined by flow cytometry.

Results

A 5-month-old previously-healthy male presented with respiratory failure and diffuse pulmonary ground glass opacities on CT scan of the chest. Laboratory evaluation revealed an undetectable IgG, normal IgA, and elevated IgM. A bronchoalveolar lavage demonstrated pulmonary alveolar proteinosis. WES demonstrated a c.608G > C mutation in the CD40L gene resulting in p.R203T. Flow cytometry demonstrated normal CD40L expression on activated T cells but absent binding of CD40-Ig to CD40L on activated patient T cells.

Conclusions

The clinical manifestations of XHIGM in our patient had several unique features, including the presentation with PAP, normal serum IgA, and expression of non-functional CD40L on activated T cells. To our knowledge, this is the first published case of PAP in a patient with XHIGM.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Al-Saud BK, Al-Sum Z, Alassiri H, Al-Ghonaium A, Al-Muhsen S, Al-Dhekri H, et al. Clinical, immunological, and molecular characterization of hyper-IgM syndrome due to CD40 deficiency in eleven patients. J Clin Immunol. 2013;33(8):1325–35.CrossRefPubMed Al-Saud BK, Al-Sum Z, Alassiri H, Al-Ghonaium A, Al-Muhsen S, Al-Dhekri H, et al. Clinical, immunological, and molecular characterization of hyper-IgM syndrome due to CD40 deficiency in eleven patients. J Clin Immunol. 2013;33(8):1325–35.CrossRefPubMed
3.
go back to reference Ferrari S, Giliani S, Insalaco A, Al-Ghonaium A, Soresina AR, Loubser M, et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A. 2001;98(22):12614–9.CrossRefPubMedPubMedCentral Ferrari S, Giliani S, Insalaco A, Al-Ghonaium A, Soresina AR, Loubser M, et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A. 2001;98(22):12614–9.CrossRefPubMedPubMedCentral
4.
go back to reference Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 2000;102(5):565–75.CrossRefPubMed Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 2000;102(5):565–75.CrossRefPubMed
5.
go back to reference Imai K, Slupphaug G, Lee WI, Revy P, Nonoyama S, Catalan N, et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol. 2003;4(10):1023–8.CrossRefPubMed Imai K, Slupphaug G, Lee WI, Revy P, Nonoyama S, Catalan N, et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol. 2003;4(10):1023–8.CrossRefPubMed
6.
go back to reference Notarangelo LD, Duse M, Ugazio AG. Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev. 1992;3(2):101–21.PubMed Notarangelo LD, Duse M, Ugazio AG. Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev. 1992;3(2):101–21.PubMed
7.
go back to reference Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore). 2003;82(6):373–84.CrossRef Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore). 2003;82(6):373–84.CrossRef
8.
go back to reference Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr. 1997;131(1 Pt 1):47–54.CrossRefPubMed Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr. 1997;131(1 Pt 1):47–54.CrossRefPubMed
9.
go back to reference Lee WI, Torgerson TR, Schumacher MJ, Yel L, Zhu Q, Ochs HD. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. Blood. 2005;105(5):1881–90.CrossRefPubMed Lee WI, Torgerson TR, Schumacher MJ, Yel L, Zhu Q, Ochs HD. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. Blood. 2005;105(5):1881–90.CrossRefPubMed
10.
go back to reference Fuleihan R, Ramesh N, Loh R, Jabara H, Rosen RS, Chatila T, et al. Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A. 1993;90(6):2170–3.CrossRefPubMedPubMedCentral Fuleihan R, Ramesh N, Loh R, Jabara H, Rosen RS, Chatila T, et al. Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A. 1993;90(6):2170–3.CrossRefPubMedPubMedCentral
11.
go back to reference DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature. 1993;361(6412):541–3.CrossRefPubMed DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature. 1993;361(6412):541–3.CrossRefPubMed
12.
go back to reference Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 1993;361(6412):539–41.CrossRefPubMed Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 1993;361(6412):539–41.CrossRefPubMed
13.
go back to reference Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 1993;72(2):291–300.CrossRefPubMed Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 1993;72(2):291–300.CrossRefPubMed
14.
go back to reference Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 1993;259(5097):990–3.CrossRefPubMed Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 1993;259(5097):990–3.CrossRefPubMed
15.
go back to reference Agematsu K, Nagumo H, Shinozaki K, Hokibara S, Yasui K, Terada K, et al. Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome. J Clin Invest. 1998;102(4):853–60.CrossRefPubMedPubMedCentral Agematsu K, Nagumo H, Shinozaki K, Hokibara S, Yasui K, Terada K, et al. Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome. J Clin Invest. 1998;102(4):853–60.CrossRefPubMedPubMedCentral
16.
go back to reference Seyama K, Nonoyama S, Gangsaas I, Hollenbaugh D, Pabst HF, Aruffo A, et al. Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. Blood. 1998;92(7):2421–34.PubMed Seyama K, Nonoyama S, Gangsaas I, Hollenbaugh D, Pabst HF, Aruffo A, et al. Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. Blood. 1998;92(7):2421–34.PubMed
17.
go back to reference Lopez-Herrera G, Maravillas-Montero JL, Vargas-Hernandez A, Berron-Ruiz L, Ramirez-Sanchez E, Yamazaki-Nakashimada MA, et al. A novel CD40LG deletion causes the hyper-IgM syndrome with normal CD40L expression in a 6-month-old child. Immunol Res. 2015;62(1):89–94.CrossRefPubMed Lopez-Herrera G, Maravillas-Montero JL, Vargas-Hernandez A, Berron-Ruiz L, Ramirez-Sanchez E, Yamazaki-Nakashimada MA, et al. A novel CD40LG deletion causes the hyper-IgM syndrome with normal CD40L expression in a 6-month-old child. Immunol Res. 2015;62(1):89–94.CrossRefPubMed
18.
go back to reference Ameratunga R, Lederman HM, Sullivan KE, Ochs HD, Seyama K, French JK, et al. Defective antigen-induced lymphocyte proliferation in the X-linked hyper-IgM syndrome. J Pediatr. 1997;131(1 Pt 1):147–50.CrossRefPubMed Ameratunga R, Lederman HM, Sullivan KE, Ochs HD, Seyama K, French JK, et al. Defective antigen-induced lymphocyte proliferation in the X-linked hyper-IgM syndrome. J Pediatr. 1997;131(1 Pt 1):147–50.CrossRefPubMed
19.
go back to reference Jain A, Atkinson TP, Lipsky PE, Slater JE, Nelson DL, Strober W. Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. J Clin Invest. 1999;103(8):1151–8.CrossRefPubMedPubMedCentral Jain A, Atkinson TP, Lipsky PE, Slater JE, Nelson DL, Strober W. Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. J Clin Invest. 1999;103(8):1151–8.CrossRefPubMedPubMedCentral
20.
go back to reference Cunningham CK, Bonville CA, Ochs HD, Seyama K, John PA, Rotbart HA, et al. Enteroviral meningoencephalitis as a complication of X-linked hyper IgM syndrome. J Pediatr. 1999;134(5):584–8.CrossRefPubMed Cunningham CK, Bonville CA, Ochs HD, Seyama K, John PA, Rotbart HA, et al. Enteroviral meningoencephalitis as a complication of X-linked hyper IgM syndrome. J Pediatr. 1999;134(5):584–8.CrossRefPubMed
21.
go back to reference Seyama K, Kobayashi R, Hasle H, Apter AJ, Rutledge JC, Rosen D, et al. Parvovirus B19-induced anemia as the presenting manifestation of X-linked hyper-IgM syndrome. J Infect Dis. 1998;178(2):318–24.CrossRefPubMed Seyama K, Kobayashi R, Hasle H, Apter AJ, Rutledge JC, Rosen D, et al. Parvovirus B19-induced anemia as the presenting manifestation of X-linked hyper-IgM syndrome. J Infect Dis. 1998;178(2):318–24.CrossRefPubMed
22.
go back to reference Leiva LE, Junprasert J, Hollenbaugh D, Sorensen RU. Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome. J Clin Immunol. 1998;18(4):283–90.CrossRefPubMed Leiva LE, Junprasert J, Hollenbaugh D, Sorensen RU. Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome. J Clin Immunol. 1998;18(4):283–90.CrossRefPubMed
23.
go back to reference Cabral-Marques O, Klaver S, Schimke LF, Ascendino EH, Khan TA, Pereira PV, et al. First report of the hyper-IgM syndrome registry of the Latin American society for immunodeficiencies: novel mutations, unique infections, and outcomes. J Clin Immunol. 2014;34(2):146–56.CrossRefPubMed Cabral-Marques O, Klaver S, Schimke LF, Ascendino EH, Khan TA, Pereira PV, et al. First report of the hyper-IgM syndrome registry of the Latin American society for immunodeficiencies: novel mutations, unique infections, and outcomes. J Clin Immunol. 2014;34(2):146–56.CrossRefPubMed
24.
go back to reference Cabral-Marques O, Schimke LF, Pereira PV, Falcai A, de Oliveira JB, Hackett MJ, et al. Expanding the clinical and genetic spectrum of human CD40L deficiency: the occurrence of paracoccidioidomycosis and other unusual infections in Brazilian patients. J Clin Immunol. 2012;32(2):212–20.CrossRefPubMed Cabral-Marques O, Schimke LF, Pereira PV, Falcai A, de Oliveira JB, Hackett MJ, et al. Expanding the clinical and genetic spectrum of human CD40L deficiency: the occurrence of paracoccidioidomycosis and other unusual infections in Brazilian patients. J Clin Immunol. 2012;32(2):212–20.CrossRefPubMed
26.
go back to reference Erdos M, Garami M, Rakoczi E, Zalatnai A, Steinbach D, Baumann U, et al. Neuroendocrine carcinoma associated with X-linked hyper-immunoglobulin M syndrome: report of four cases and review of the literature. Clin Immunol. 2008;129(3):455–61.CrossRefPubMed Erdos M, Garami M, Rakoczi E, Zalatnai A, Steinbach D, Baumann U, et al. Neuroendocrine carcinoma associated with X-linked hyper-immunoglobulin M syndrome: report of four cases and review of the literature. Clin Immunol. 2008;129(3):455–61.CrossRefPubMed
27.
go back to reference Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol. 1997;158(2):977–83.PubMed Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol. 1997;158(2):977–83.PubMed
28.
go back to reference Jesus AA, Duarte AJ, Oliveira JB. Autoimmunity in hyper-IgM syndrome. J Clin Immunol. 2008;28 Suppl 1:S62–6.CrossRefPubMed Jesus AA, Duarte AJ, Oliveira JB. Autoimmunity in hyper-IgM syndrome. J Clin Immunol. 2008;28 Suppl 1:S62–6.CrossRefPubMed
29.
go back to reference Kumanogoh A, Wang X, Lee I, Watanabe C, Kamanaka M, Shi W, et al. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J Immunol. 2001;166(1):353–60.CrossRefPubMed Kumanogoh A, Wang X, Lee I, Watanabe C, Kamanaka M, Shi W, et al. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J Immunol. 2001;166(1):353–60.CrossRefPubMed
30.
go back to reference Lacroix-Desmazes S, Resnick I, Stahl D, Mouthon L, Espanol T, Levy J, et al. Defective self-reactive antibody repertoire of serum IgM in patients with hyper-IgM syndrome. J Immunol. 1999;162(9):5601–8.PubMed Lacroix-Desmazes S, Resnick I, Stahl D, Mouthon L, Espanol T, Levy J, et al. Defective self-reactive antibody repertoire of serum IgM in patients with hyper-IgM syndrome. J Immunol. 1999;162(9):5601–8.PubMed
31.
go back to reference Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell. 1996;87(2):319–29.CrossRefPubMed Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell. 1996;87(2):319–29.CrossRefPubMed
32.
go back to reference Herve M, Isnardi I, Ng YS, Bussel JB, Ochs HD, Cunningham-Rundles C, et al. CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. J Exp Med. 2007;204(7):1583–93.CrossRefPubMedPubMedCentral Herve M, Isnardi I, Ng YS, Bussel JB, Ochs HD, Cunningham-Rundles C, et al. CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. J Exp Med. 2007;204(7):1583–93.CrossRefPubMedPubMedCentral
33.
go back to reference Tomizawa D, Imai K, Ito S, Kajiwara M, Minegishi Y, Nagasawa M, et al. Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience. Am J Hematol. 2004;76(1):33–9.CrossRefPubMed Tomizawa D, Imai K, Ito S, Kajiwara M, Minegishi Y, Nagasawa M, et al. Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience. Am J Hematol. 2004;76(1):33–9.CrossRefPubMed
34.
go back to reference Rezaei N, Notarangelo LD. Hematopoietic stem cell transplantation for hyper-IgM syndromes. Pediatr Transplant. 2013;17(1):1–2.CrossRefPubMed Rezaei N, Notarangelo LD. Hematopoietic stem cell transplantation for hyper-IgM syndromes. Pediatr Transplant. 2013;17(1):1–2.CrossRefPubMed
35.
go back to reference Mitsui-Sekinaka K, Imai K, Sato H, Tomizawa D, Kajiwara M, Nagasawa M, et al. Clinical features and hematopoietic stem cell transplantations for CD40 ligand deficiency in Japan. J Allergy Clin Immunol. 2015;136(4):1018–24.CrossRefPubMed Mitsui-Sekinaka K, Imai K, Sato H, Tomizawa D, Kajiwara M, Nagasawa M, et al. Clinical features and hematopoietic stem cell transplantations for CD40 ligand deficiency in Japan. J Allergy Clin Immunol. 2015;136(4):1018–24.CrossRefPubMed
36.
go back to reference Gennery AR, Khawaja K, Veys P, Bredius RG, Notarangelo LD, Mazzolari E, et al. Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993–2002. Blood. 2004;103(3):1152–7.CrossRefPubMed Gennery AR, Khawaja K, Veys P, Bredius RG, Notarangelo LD, Mazzolari E, et al. Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993–2002. Blood. 2004;103(3):1152–7.CrossRefPubMed
37.
go back to reference Sato T, Kobayashi R, Toita N, Kaneda M, Hatano N, Iguchi A, et al. Stem cell transplantation in primary immunodeficiency disease patients. Pediatr Int. 2007;49(6):795–800.CrossRefPubMed Sato T, Kobayashi R, Toita N, Kaneda M, Hatano N, Iguchi A, et al. Stem cell transplantation in primary immunodeficiency disease patients. Pediatr Int. 2007;49(6):795–800.CrossRefPubMed
38.
go back to reference Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349(26):2527–39.CrossRefPubMed Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349(26):2527–39.CrossRefPubMed
39.
go back to reference Hamvas A, Cole FS, Nogee LM. Genetic disorders of surfactant proteins. Neonatology. 2007;91(4):311–7.CrossRefPubMed Hamvas A, Cole FS, Nogee LM. Genetic disorders of surfactant proteins. Neonatology. 2007;91(4):311–7.CrossRefPubMed
40.
go back to reference Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166(2):215–35.CrossRefPubMed Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166(2):215–35.CrossRefPubMed
41.
go back to reference Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014;123(6):809–21.CrossRefPubMedPubMedCentral Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014;123(6):809–21.CrossRefPubMedPubMedCentral
42.
go back to reference Mahut B, Delacourt C, Scheinmann P, de Blic J, Mani TM, Fournet JC, et al. Pulmonary alveolar proteinosis: experience with eight pediatric cases and a review. Pediatrics. 1996;97(1):117–22.PubMed Mahut B, Delacourt C, Scheinmann P, de Blic J, Mani TM, Fournet JC, et al. Pulmonary alveolar proteinosis: experience with eight pediatric cases and a review. Pediatrics. 1996;97(1):117–22.PubMed
43.
go back to reference Colon Jr AR, Lawrence RD, Mills SD, O’Connell EJ. Childhood pulmonary alveolar proteinosis (PAP). Report of a case and review of the literature. Am J Dis Child. 1971;121(6):481–5.CrossRefPubMed Colon Jr AR, Lawrence RD, Mills SD, O’Connell EJ. Childhood pulmonary alveolar proteinosis (PAP). Report of a case and review of the literature. Am J Dis Child. 1971;121(6):481–5.CrossRefPubMed
44.
go back to reference Fisher M, Roggli V, Merten D, Mulvihill D, Spock A. Coexisting endogenous lipoid pneumonia, cholesterol granulomas, and pulmonary alveolar proteinosis in a pediatric population: a clinical, radiographic, and pathologic correlation. Pediatr Pathol. 1992;12(3):365–83.CrossRefPubMed Fisher M, Roggli V, Merten D, Mulvihill D, Spock A. Coexisting endogenous lipoid pneumonia, cholesterol granulomas, and pulmonary alveolar proteinosis in a pediatric population: a clinical, radiographic, and pathologic correlation. Pediatr Pathol. 1992;12(3):365–83.CrossRefPubMed
45.
go back to reference Ruben FL, Talamo TS. Secondary pulmonary alveolar proteinosis occurring in two patients with acquired immune deficiency syndrome. Am J Med. 1986;80(6):1187–90.CrossRefPubMed Ruben FL, Talamo TS. Secondary pulmonary alveolar proteinosis occurring in two patients with acquired immune deficiency syndrome. Am J Med. 1986;80(6):1187–90.CrossRefPubMed
46.
go back to reference Patiroglu T, Akyildiz B, Patiroglu TE, Gulmez IY. Recurrent pulmonary alveolar proteinosis secondary to agammaglobulinemia. Pediatr Pulmonol. 2008;43(7):710–3.CrossRefPubMed Patiroglu T, Akyildiz B, Patiroglu TE, Gulmez IY. Recurrent pulmonary alveolar proteinosis secondary to agammaglobulinemia. Pediatr Pulmonol. 2008;43(7):710–3.CrossRefPubMed
47.
go back to reference Suttles J, Stout RD. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol. 2009;21(5):257–64.CrossRefPubMed Suttles J, Stout RD. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol. 2009;21(5):257–64.CrossRefPubMed
Metadata
Title
X-linked Hyper IgM Syndrome Presenting as Pulmonary Alveolar Proteinosis
Authors
Joel Gallagher
Juan Adams
Mary Hintermeyer
Troy R. Torgerson
Jesus Lopez-Guisa
Hans D. Ochs
Sara Szabo
Mina Salib
James Verbsky
John Routes
Publication date
01-08-2016
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 6/2016
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-016-0307-0

Other articles of this Issue 6/2016

Journal of Clinical Immunology 6/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.